HPV type infection in different anogenital sites among HIV-positive Brazilian women

1750-9378-3-5 1750-9378 Research article HPV type infection in different anogenital sites among HIV-positive Brazilian women Gonçalves Alice G Maria epigin@uol.com.br Randi Giorgia randi@marionegri.it Arslan Annie arslan@iarc.fr Villa L Luisa villall@hotmail.com Burattini N Marcelo mnburrat@usp.br Franceschi Silvia franceschi@iarc.fr Donadi Eduardo Antonio epigin@uol.com.br Massad Eduardo emassad@usp.br

Division of Clinical Immunology, University of São Paulo, São Paulo, Brazil

Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy

International Agency for Research on Cancer, Lyon, France

Department of Virology, Ludwig Institute for Cancer Research, São Paulo, Brazil

School of Medicine, Department of Pathology, University of São Paulo, São Paulo, Brazil

Infectious Agents and Cancer 1750-9378 2008 3 1 5 http://www.infectagentscancer.com/content/3/1/5 18341690 10.1186/1750-9378-3-5 26 9 2006 14 3 2008 14 3 2008 2008 Gonçalves et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objectives

To evaluate the prevalence of human papillomavirus (HPV) types, and risk factors for HPV positivity across cervix, vagina and anus, we conducted a study among 138 women with human immunodeficiency virus (HIV).

Goal

Compare the prevalence of different HPV types and the risk factors for HPV positivity in three sites.

Results

The most frequently detected HPV types in all sites were, in decreasing order, HPV16, 53, 18, 61 and 81. Agreement between the cervix and vagina was good (kappa 0.60 – 0.80) for HPV16 and 53 and excellent (Kappa > 0.80) for HPV18 and 61. HPV positivity was inversely associated with age for all combinations including the anal site.

Conclusion

In HIV positive women, HPV18 is the most spread HPV type found in combinations of anal and genital sites. The relationship of anal to genital infection has implications for the development of anal malignancies. Thus, the efficacy of the current HPV vaccine may be considered not only for the cervix, but also for prevention of HPV18 anal infection among immunossuppressed individuals.

Background

More than 1.7 million people were living with human immunodeficiency virus (HIV) infection in Latin America at the end of 2004, and Brazilian women made up more than one-third (610,000) of this population 1. Among women from 15–24 years of age, the prevalence of HIV infection in Brazil is estimated to be 0.5%. With the advent of antiretroviral drugs in Brazil, median survival time for people diagnosed with AIDS has increased from 18 to 58 months 2.

Epidemiological and laboratory data have demonstrated that persistent infection with high-risk human papillomavirus (HPV) types (like 16, 18, 31, 33, 39, 45, 52, 53, 56, 58, 59, 66, 68, 73, 82) is an essential step in the development of invasive cervical cancer and the majority of anal cancer 3. Compared to HIV-negative women, HIV-positive women have an increased incidence and persistence of HPV infection and a concomitant increased risk of developing squamous intraepithelial lesions and cervical cancer 4567.

In addition, compared to HIV-negative women, HIV-positive women show a higher occurrence of multiple-type HPV infection 8910 and a relatively lower proportion of HPV16 11. Little information is available on the concomitant prevalence of HPV infection in different anogenital sites 12, notably in the anal area 1314.

In this study we have compared the prevalence of different HPV types and the risk factors for HPV positivity in three sites (i.e., cervical, vaginal and anal area).

Methods

Patients

Study methods have been reported elsewhere 8. Briefly, a cross-sectional study was conducted among 138 HIV-positive women, aged 19–57 (mean age = 31 years), who attended the Center of Reference in AIDS of Santos, São Paulo, Brazil between June 1996 and April 1997. Patients who reported previous hysterectomy, virgins or those who were not able to provide an informed consent form were excluded from the study. All women underwent HIV serological testing with Western blot confirmation (Cambridge Biotech Corporation, Worcester, Massachusetts, USA). CD4 cell count was performed on the date of the visit or within three months thereafter. CD4 counts were > 500 cells/mm³in 24.6% women, between 200–499 cells/mm³in 37.0%, and < 200 cells/mm³in 38.4%.

The same gynecologist applied a standard questionnaire for all patients to elicit information on sociodemographic characteristics, smoking habits, history of drug addiction, sexual behavior and use of condom. The Ethics Committee of the Medical School of the University of São Paulo, Brazil, approved the study protocol, and all participants signed informed consent forms.

Sample collection

The same gynecologist collected exfoliated cells from 1) ectocervix, 2) vagina and 3) anal area, in that order, with separate sterile brushes, and stored in separate flasks in phosphate-buffered saline solution (PBS). To obtain samples for anal collection, individual disposable brushes moistened in sterile PBS were inserted into the anal canal and were rotated 360° as they were withdrawn.

HPV detection and typing

After collection, cells remaining in the collection devices were washed out into a sterile buffered solution and kept at -20°C for HPV analysis. Beta-globin amplification was used to assess specimen adequacy for HPV DNA detection. Polymerase chain reaction (PCR)-based assays were carried out in the Laboratorio de Patologia e Hemoterapia do Hospital do Cancer, Fundação Antonio Prudente, São Paulo, Brazil 15.

PCR-positive samples were further typed by restriction fragment length polymorphism according to Bernard et al. 16, allowing the recognition of more than 42 HPV types (HPV6,11, 13, 16, 18, 26, 31, 32, 33, 34, 35, 39, 40, 42, 44, 45, 51, 52, 53, 54, 55, 56, 57, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 83, 84, LVX100 and CP6108). The following restriction enzymes were used: Bam HI, Dde I, Hae III, Hinf I, Pst I, Rsa I and Sau 3a I (Gibco BRL-Life Technologies, Los Angeles, California, USA). The identification of HPV types was performed by comparing the pattern of amplified bands with those attributed to each virus type. HPV types were classified as high-risk (or probably high-risk) and low-risk types as in Muñoz et al. 17. Other HPV types that could not be identified in this study were considered unidentified (HPVX).

Statistical analysis

The Kappa statistic was used to calculate the agreement between HPV positivity at the cervical vs vaginal or anal sites. The concordance rate was considered fair to good if Kappa values were between 0.60–0.80, and excellent if greater than 0.80. Agreement for any HPV type is defined as presence of at least one common HPV type in the 2 or 3 combined sites. ORs for detection of HPV infection and corresponding 95% CIs were calculated separately for each anogenital site and for each combination of 2 or 3 sites by means of unconditional regression equations adjusted for age (< 25, 25–34, ≥ 35). The analyses were repeated with adjustment for age and CD4 count (< 200, 200–499, ≥ 500).

Results

HPV prevalence by anogenital site

The prevalence of HPV infection among HIV-positive women did not differ significantly between the three anogenital sites under study. The prevalence was 61.6% in the cervix, 65.9% in the vagina, and 63.7% in the anal area. The same similarity is seen when high-risk HPV types are considered, in the cervix (36.2%), vagina (42.8%) and the anal area (43.1%). In respect to low-risk HPV types, the prevalence was 34.1% in the cervix, 35.5% in the vagina and 33.3% in the anal area. Multiple HPV infections occurred in 41.2% of HPV-positive cervical samples, 48.4% of HPV-positive vaginal samples and 44.6% of HPV-positive anal samples. The prevalence of HPV types according to the risk category in the studied female population was described elsewhere 18.

In the cervix, the most frequent high-risk HPV types were HPV16 and 53 (n = 13 each type) and HPV18 (n = 12) (Table 1). HPV61 and 81 were the most frequent low-risk HPV types (n = 11 and 9 respectively). For 9.4% of the samples the HPV type could not be characterized.

Table 1

Prevalence of 23 HPV types by collected site among 138 HIV-positive women. Santos, São Paulo, Brazil, 1996–1997

Site

Cervix

Vagina

Anal^a

Single

Multiple

Total (%)

Single

Multiple

Total (%)

Single

Multiple

Total (%)

HPV -

53 (38.4)

47 (34.1)

37 (36.3)

HPV +

85 (61.6)

91 (65.9)

65 (63.7)

HR HPV+

51 (37.0)

59 (42.8)

44 (43.1)

LR HPV+

47 (34.1)

49 (35.5)

35 (34.3)

High-risk

13 (9.4)

17 (12.3)

9 (8.8)

12 (8.7)

12 (11.8)

5 (3.6)

6 (4.3)

3 (2.9)

7 (5.1)

8 (5.8)

6 (5.9)

1 (0.7)

1 (1.0)

2 (1.4)

1 (1.0)

1 (0.7)

2 91.4)

0 (0.0)

13 (9.4)

15 (10.9)

13 (12.7)

1 (0.7)

2 (1.4)

1 (1.0)

3 (2.2)

3 (2.9)

1 (0.7)

0 (0.0)

0 (0.00

3 (2.2)

4 (3.9)

2 (1.4)

4 (2.9)

1 (1.0)

1 (0.7)

0 (0.0)

2 (1.4)

0 (0.0)

Subtotal

Low-risk

4 (2.9)

8 (7.8)

7 (5.1)

6 (5.5)

1 (0.7)

0 (0.0)

1 (0.7)

1 (1.0)

2 (1.4)

4 (2.9)

2 (1.8)

2 (1.4)

3 (2.2)

1 (1.0)

11 (8.0)

8 (7.3)

1 (0.7)

3 (2.7)

1 (0.7)

0 (0.0)

1 (1.0)

2 (1.4)

1 (0.7)

0 (0.0)

2 (1.4)

3 (2.2)

1 (1.0)

1 (0.7)

0 (0.0)

2 (1.4)

1 (1.0)

2 (1.4)

4 (2.9)

1 (1.0)

9 (6.5)

11 (8.0)

5 (4.6)

6 (4.3)

4 (2.9)

3 (2.7)

1 (0.7)

1 (1.0)

Subtotal

Unknown

13 (9.4)

18 (13.0)

12 (11.8)

^aPresented for 102 HIV-positive women. HPV = human papillomavirus; HIV = human immunodeficiency virus; HR = High-risk; LR = low-risk

Similarly, in the vagina, the most frequent high-risk HPV types detected were HPV16, 53 and 18 (n = 17, 15 and 12, respectively) (Table 1), while the most frequent low-risk HPV types were HPV61 and 81 (n = 11 for each). Thirteen % of vaginal samples were HPV positive but the HPV type could not be characterized.

In the anal area, the most frequently detected high-risk HPV types were, in decreasing order, HPV53 (n = 13), 18 (n = 12), and 16 (n = 9). The most frequent low-risk HPV types were HPV 61 and 6 (n = 8 for each). In 11.8% of anal samples the HPV type could not be characterized. HPV6, but not HPV11, tended to be more frequent in the anal area than in the cervix or vagina (7.8% in the anal area vs 2.9% in each other site).

In respect to cervical and vaginal sites, agreement for any HPV type positivity was 78.3% (Kappa value = 0.53 for any type) and varied from 92.8% (HPV16) to 98.6% (HPV61 and HPV6). Kappa values above 0.80 were found for HPV18, 33 and 61. When cervical and anal sites were compared, agreement for positivity for any HPV type was found in 68.6% of women (Kappa value = 0.31) (Table 2). The Kappa value was particularly low for HPV16 (0.11), but was relatively elevated for HPV18 (0.69), especially concerning the combination among the three sites (0.72).

Table 2

Agreement of HPV type detection by collected site among 138 HIV-positive women. Santos, São Paulo, Brazil: 1996–1997

Cervix: Vagina

Cervix: Anus^a

Cervix, Vagina, Anus^a

HPV type

Cervix only

Vagina only

Both

Agreement (Kappa value)

Cervix only

Anal only

Both

Agreement (Kappa value)

Any of the three

All three

Agreement (Kappa value)

92.8 (0.63)

84.3 (0.11)^b

79.4 (0.32)

97.1 (0.82)

94.1 (0.69)

92.2 (0.72)

95.7 (0.76)

83.3 (0.23)

81.4 (0.45)

98.6 (0.74)

95.1 (0.52)

94.1 (0.55)

97.1 (0.70)

92.2 (0.16)

91.2 (0.33)

98.6 (0.90)

89.2 (0.29)

89.2 (0.54)

Any type

78.3 (0.53)

68.6 (0.31)

59.8 (0.40)

^aAvailable for 102 women only; ^bNon-significant Kappa value. HPV = human papillomavirus; HIV = human immunodeficiency virus.

Risk factors for associations between sites for any HPV positivity

As shown in Table 3, HPV positivity were inversely associated with age in three combinations of anogenital sites (cervical+anal; vaginal+anal and cervical+vaginal+anal), all of them including anal site. No association emerged in any site between HPV positivity and smoking habits, history of drug addiction, commercial sex work and condom use, and number of years since HIV diagnosis.

Table 3

ORs ofHPV positivity and corresponding 95% CIs according to selected characteristics among 138 HIV-positive women^a. Santos, São Paulo, Brazil, 1996–1997

Cervical+Vaginal

Cervical+Anal^b

Vaginal+Anal^b

Cervical+Vaginal+Anal^b

Tot. No

Pos. (%)

OR^c

95% CI

Tot. No

Pos. (%)

OR^c

95% CI

Tot. No

Pos. (%)

OR^c

95% CI

Tot. No

Pos. (%)

OR^c

95% CI

Age (years)

≥ 35

38.5

10.0

13.3

6.7

25–34

49.3

1.6

0.7–3.4

27.3

3.4

0.9–12.8

34.6

3.4

1.0–11.3

27.3

5.3

1.1–24.8

< 25

58.3

2.2

0.8–6.3

47.1

8.0

1.7–36.8

41.2

4.6

1.1–19.0

35.3

7.6

1.3–43.8

p for trend

0.12

0.006

0.03

0.02

Tobacco smoking

Never smoker

45.5

31.3

21.9

Ex-smoker

45.5

1.1

0.4–2.8

30.8

1.1

0.3–3.8

34.6

1.2

0.4–3.7

30.8

1.7

0.5–6.1

Current smoker

50.8

1.3

0.6–3.0

18.2

0.5

0.2–1.7

25.0

0.8

0.3–2.2

18.2

0.9

0.3–2.9

p for trend

0.46

0.22

0.52

0.60

Drug addict

Never

45.6

25.8

21.0

52.8

1.3

0.6–2.8

29.2

1.1

0.4–3.2

45.8

2.2

0.8–6.2

29.2

1.4

0.5–4.2

Current

47.8

1.0

0.4–2.7

18.8

0.7

0.2–2.9

18.8

0.6

0.2–2.6

18.8

0.8

0.2–3.5

p for trend

0.80

0.70

0.99

0.98

Years since HIV diagnosis

≤ 1

46.3

27.5

32.5

22.5

2–4

39.5

0.8

0.4–1.9

60.529.4

1.3

0.4–3.8

32.4

1.0

0.4–2.8

26.5

1.3

0.4–4.2

≥ 5

56.4

1.8

0.7–4.2

19.2

0.7

0.2–2.8

23.1

0.5

0.2–1.9

19.2

0.8

0.2–3.1

p for trend

0.25

0.73

0.38

0.81

CD4 count/mm³

≥ 500

41.2

15.0

10.0

200–499

49.0

1.8

0.7–4.7

23.1

4.2

0.8–22.2

30.8

4.8

1.0–22.7

23.1

5.7

0.9–34.1

< 200

59.9

1.8

0.7–4.6

32.6

5.9

1.2–28.6

34.9

5.0

1.1–22.4

27.9

6.2

1.1–34.9

p for trend

0.24

0.03

0.06

Commercial sex worker

Never

107

46.7

24.4

26.8

20.7

Ever

51.6

1.2

0.5–2.6

30.0

1.2

0.4–3.8

40.0

1.7

0.6–4.8

30.0

1.5

0.5–4.6

Lifetime number of sexual partners

≤ 2

41.2

26.9

30.8

26.9

3–5

52.3

1.5

0.6–3.8

25.7

0.9

0.3–2.9

25.7

0.7

0.2–2.3

17.1

0.5

0.1–1.8

≥ 6

48.3

1.2

0.5–3.0

24.4

0.7

0.2–2.3

31.7

0.8

0.3–2.6

24.4

0.7

0.2–2.2

p for trend

0.63

0.32

0.85

0.53

Recent sexual partners^d

43.8

21.4

26.2

21.4

47.3

1.0

0.5–2.1

25.5

0.8

0.3–2.4

27.5

0.8

0.3–2.0

19.6

0.6

0.2–1.7

≥ 2

76.9

3.5

0.8–15.0

44.4

2.2

0.5–10.7

55.6

2.6

0.5–12.0

44.4

2.0

0.4–9.5

p for trend

0.21

0.56

0.52

0.83

Condom use^d

Yes

47.8

25.5

27.7

19.2

60.0

1.7

0.6–4.8

38.5

2.0

0.5–7.6

46.2

2.4

0.7–8.8

38.5

2.9

0.7–11.6

Anal intercourse

Never

48.5

19.6

Ever

47.2

0.9

0.5–1.8

31.4

1.7

0.6–4.3

39.2

2.4

0.97–6.0

25.5

1.2

0.5–3.2

^aSome figures do not add up to the total due to missing values; ^bPresented for 102 HIV-positive women; ^cAdjusted for age. HPV = human papillomavirus; ^drelative to the last 6 months preceding interview; HIV = human immunodeficiency virus; OR = odds ratio; CI = confidence intervals.

Anal intercourse showed an association of borderline statistical significance in the combination vaginal + anal for HPV positivity (OR: 2.4; 95% CI: 0.97–6.0), but not elsewhere. Nevertheless, condom use did not show associations with HPV positivity at all sites.

Discussion

Approximately two-thirds of HIV-positive women in our study from Brazil were infected by HPV and the prevalence of HPV infection was similar in the cervix, vagina and anal area. This also held true for the prevalence of the most frequently detected individual HPV types, notably HPV11, 16, 18, 53 and 61, and for the frequency of multiple-type infections. However, the same HPV type(s) were not always present in the three examined anogenital areas and the agreement in the detection of individual types was better between the cervix and the vagina than between the cervix and the anal area. The type most frequently detected at all three sites was HPV18, mainly on account of its high prevalence in the anal area. Recently, Castle et al. 19 reported that some HPV types (e.g., HPV61, 71 and 72), were more frequently detected in vaginal specimens from hysterectomized women compared to those who had not undergone hysterectomy. Simultaneous HPV infection in different anogenital sites is considered a risk factor for the concomitant occurrence of anal and cervical lesions, especially in HIV-positive women 202122.

The factors most clearly associated with HPV positivity among HIV-positive women in our study agree with findings from HIV-negative women 2324. Although the small number of women available did not allow most presented ORs to reach statistical significance, we did show higher HPV positivity below age 25 than at age 35 or older, as well as among women who reported two recent sexual partners or more. These findings are consistent with the report that recent sexual partners are a stronger determinant of HPV positivity than the lifetime number of sexual partners 25. No consistent relationship between HPV positivity and smoking habits or condom use have emerged among HIV-negative women 2324.

Two characteristics stand out as being more strongly associated with HPV positivity in the anal area than in the cervix and vagina, one being history of anal intercourse. This finding suggests that anal infection is associated among women, as it is among bisexual and homosexual men, to direct HPV exposure 2226. Anal infection, however, can also be detected in women who do not report anal intercourse, particularly if a concomitant infection occurs at a genital site 2728. The other factor that appeared more strongly associated with anal than cervical or vaginal HPV infection was low CD4 counts, thus suggesting that immunosupression may particularly facilitate HPV infection and maybe persistence in the anal area.

One of the limitations of this work is its small sample size. As a consequence, many relatively strong associations did not attain statistical significance. Furthermore, the cross-sectional design does not allow for the capture of the dynamic nature of HPV infections. One of the strengths of this study is the wide range of HPV types tested for at different anogenital sites in HIV-positive women.

In conclusion, our study showed that high prevalences of HPV infection can be found in the entire lower genital tract in HIV-positive women. In particular, the anal area may represent a reservoir of HPV infection, notably HPV6 and 18. It will thus be important to evaluate the efficacy of the current vaccine against HPV 2930 to prevent not only HPV infection in the cervix but also in the anal area, among immunosuppressed individuals.

Acknowledgements

M.A.G. Gonçalves was a visiting scientist at IARC, Lyon, France, during the writing of the manuscript. We acknowledge Ms T. Perdrix-Thoma for technical assistance.

Latin America UNAIDS/WHO UNAIDS/WHO, ed. AIDS Epidemic Update: December 2004. Geneva: UNAIDS/WHO 2004 57 61 Dramatic improvement in survival among adult Brazilian AIDS patients Marins JR Jamal LF Chen SY Barros MB Hudes ES Barbosa AA Chequer P Teixeira PR Hearst N AIDS 2003 17 1675 1682 10.1097/00002030-200307250-00012 12853750 Monographs on the Evaluation of Carcinogenic Risks to Humans IARC Human papillomavirus Lyon: International Agency for Research on Cancer 1995 64 A longitudinal study of human papillomavirus carriage in human immunodeficiency virus-infected and human immunodeficiency virus-uninfected women Minkoff H Feldman J DeHovitz J Landesman S Burk R Am J Obstet Gynecol 1998 178 982 986 10.1016/S0002-9378(98)70535-6 9609571 Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women Ahdieh L Klein RS Burk R Cu-Uvin S Schuman P Duerr A Safaeian M Astemborski J Daniel R Shah K J Infect Dis 2001 184 682 690 10.1086/323081 11517428 Risk of cancer in persons with AIDS in Italy, 1985–1998 Dal Maso L Franceschi S Polesel J Braga C Piselli P Crocetti E Falcini F Guzzinati S Zanetti R Vercelli M Rezza G Cancer and AIDS Registry Linkage study Br J Cancer 2003 89 94 100 10.1038/sj.bjc.6601017 12838307 Factors predicting the persistence of genital human papillomavirus infections and PAP smear abnormality in HIV-positive and HIV-negative women during prospective follow-up Branca M Garbuglia AR Benedetto A Cappiello T Leoncini L Migliore G Agarossi A Syrjanen K DIANAIDS Collaborative Study Group Int J STD AIDS 2003 14 417 425 10.1258/095646203765371321 12816671 Relationship between human papillomavirus (HPV) genotyping and genital neoplasia in HIV-positive patients of Santos City, Sao Paulo, Brazil Gonçalves MA Massad E Burattini MN Villa LL Int J STD AIDS 1999 10 803 807 10.1258/0956462991913583 10639061 Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women Palefsky JM Minkoff H Kalish LA Levine A Sacks HS Garcia P Young M Melnick S Miotti P Burck R J Natl Cancer Inst 1999 91 226 236 10.1093/jnci/91.3.226 10037100 Incidence of cervical squamous intraepithelial lesions in HIV-infected women Ellerbrock TV Chiasson MA Bush TJ Sun XW Sawo D Brudney K Wright TC JAMA 2000 283 1031 1037 10.1001/jama.283.8.1031 10697063 Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women Strickler HD Palefsky JM Shah KV Anastos K Klein RS Minkoff H Duerr A Massad LS Celentano DD Hall C Fazzari M Cu-Uvin S Bacon M Schuman P Levine AM Durante AG Gange S Melnick S Burk RD J Natl Cancer Inst 2003 95 1062 1071 12865452 Concordance of prevalence of human papillomavirus DNA in anogenital and oral infections in a high-risk population Canadas MP Bosch FX Junquera ML Ejarque M Fonte R Ordonez E de SanJose S J Clin Microbiol 2004 42 1330 1332 356845 15004111 10.1128/JCM.42.3.1330-1332.2004 Anal human papillomavirus DNA screening by Hybrid Capture II in human immunodeficiency virus-positive patients with or without anal intercourse Drobacheff C Dupont P Mougin C Bourezane Y Challier B Fantoli M Bettinger B Laurent R Eur J Dermatol 2003 13 367 371 12948917 Incidence of anal cytological abnormalities in a cohort of human immunodeficiency virus-infected women Durante AJ Williams AB Da Costa M Darragh TM Khoshnood K Palefsky JM Cancer Epidemiol Biomarkers Prev 2003 12 638 642 12869403 The use of polymerase chain reaction amplification for the detection of human papillomaviruses Manos MM Wright DT Lewis AJ Molecular diagnosis of human cancer: Cancer cells New York: Cold Spring Harbor Press Furth M, Greaves M 1989 209 214 Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms Bernard HU Chan SY Manos MM Ong CK Villla LL Delius H Peyton CL Bauer HM Wheeler CM J Infect Dis 1994 170 1077 1085 7963696 Epidemiologic classification of human papillomavirus types associated with cervical cancer Muñoz N Bosch FX de Sanjosé S Herrero R Castellsagué X Shah KV Snijders PJ Meijer CJ International Agency for Research on Cancer Multicenter Cervical Cancer Study Group N Engl J Med 2003 348 518 527 10.1056/NEJMoa021641 12571259 Risk factors associated with genital warts in HIV-positive Brazilian women Gonçalves MA Burattini MN Donadi EA Massad E Tumori 2003 89 9 15 A population-based study of vaginal human papillomavirus infection in hysterectomized women Castle PE Schiffman M Bratti MC Hildesheim A Herrero R Hutchinson ML Rodriguez AC Wacholder S Sherman ME Kendall H Viscidi RP Jeronimo J Schussler JE Burk RD J Infect Dis 2004 190 458 467 10.1086/421916 15243917 Prevalence of anal human papillomavirus infection and anal cytologic abnormalities in HIV-seropositive women Hillemanns P Ellerbrock TV McPhillips S Dole P Alperstein S Johnson D Sun XW Chiasson MA Wright TC AIDS 1996 10 1641 1647 8970684 Anal and cervical abnormality in women – prediction by human papillomavirus tests Melbye M Smith E Wohlfahrt J Osterlind A Orholm M Bergmann OJ Mathiesen L Darragh TM Palefsky JM Int J Cancer 1996 68 559 564 10.1002/(SICI)1097-0215(19961127)68:5<559::AID-IJC1>3.0.CO;2-Y 8938134 Prevalence and risk factors for anal squamous intraepithelial lesions in women Holly EA Ralston ML Darragh TM Greenblatt RM Jay N Palefsky JM J Natl Cancer Inst 2001 93 843 849 10.1093/jnci/93.11.843 11390533 Smoking and cervical cancer: pooled analysis of the IARC multi-centric case – control study Plummer M Herrero R Franceschi S Meijer CJ Snijders PJ Bosch FX de Sanjosé S Muñoz N International Agency for Research on Cancer Multicenter Cervical Cancer Study Group Cancer Causes Control 2003 14 805 814 10.1023/B:CACO.0000003811.98261.3e 14682438 Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study Thomas JO Herrero R Omigbodun AA Ojemakinde K Ajavi IO Fawole A Oladepo O Smith JS Arslan A Muñoz N Snijders PJ Meijer CJ Franceschi S Br J Cancer 2004 90 638 645 10.1038/sj.bjc.6601515 14760378 Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort Deacon JM Evans CD Yule R Desai M Binns W Taylor C Peto J Br J Cancer 2000 83 1565 1572 10.1054/bjoc.2000.1523 11076670 A population-based study of squamous cell vaginal cancer: HPV and cofactors Daling JR Madeleine MM Schwartz SM Shera KA Carter JJ McKnight B Porter PL Galloway DA McDougall JK Tamimi H Gynecol Oncol 2002 84 263 270 10.1006/gyno.2001.6502 11812085 Anal and cervical human papillomavirus infection and risk of anal and cervical epithelial abnormalities in human immunodeficiency virus-infected women Williams AB Darragh TM Vranizan K Ochia C Moss AR Palefsky JM Obstet Gynecol 1994 83 205 211 8290181 Human papillomavirus infection and abnormal cytology of the anus in HIV-infected and uninfected adolescents Moscicki AB Durako SJ Houser J Ma Y Murphy DA Darragh TM Farhat S Wilson CM AIDS 2003 17 311 320 10.1097/00002030-200302140-00004 12556684 Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial Villa LL Costa RL Petta CA Andrade R Ault K Giuliano A Wheeler C Koutsky L Malm C Lehtinen M Skjeldestad FE Olsson SE Steinwall M Brown DR Kurman RJ Ronnett BM Stoler MH Ferenczy A Harper DM Tamms GM Yu J Lupinacci L Railkar R Taddeo FJ Jansen KU Esser MT Sings HL Saah AJ Barr E Lancet Oncol 2005 6 271 278 10.1016/S1470-2045(05)70101-7 15863374 Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial Harper DM Franco EL Wheeler CM Moscicki A Romanowski B Roteli-Martins C Jenkins D Schuind A Costa Clemens S Dubin G HPV Vaccine Study Group Lancet 2006 367 1247 55 10.1016/S0140-6736(06)68439-0 16631880